Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
radiopharmaceutical |
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
V10BX03
|
| gptkbp:CASNumber |
888504-28-7
|
| gptkbp:chemicalFormula |
gptkb:RaCl2
|
| gptkbp:containsElement |
gptkb:chlorine
gptkb:radium-223 |
| gptkbp:developedBy |
gptkb:Bayer
|
| gptkbp:discoveredBy |
Algeta ASA
|
| gptkbp:halfLife |
11.4 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
radium Ra 223 dichloride
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Xofigo
|
| gptkbp:mechanismOfAction |
alpha particle emission damages cancer cells in bone metastases
|
| gptkbp:molecularWeight |
297.89 g/mol
|
| gptkbp:radioactive |
true
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea neutropenia thrombocytopenia |
| gptkbp:UNII |
8QX8J1J15H
|
| gptkbp:usedFor |
treatment of metastatic castration-resistant prostate cancer
|
| gptkbp:bfsParent |
gptkb:Xofigo
|
| gptkbp:bfsLayer |
7
|